Literature DB >> 16633902

Creatine and antioxidant treatment prevent the inhibition of creatine kinase activity and the morphological alterations of C6 glioma cells induced by the branched-chain alpha-keto acids accumulating in maple syrup urine disease.

Cláudia Funchal1, Patrícia Fernanda Schuck, André Quincozes Dos Santos, Maria Caroline Jacques-Silva, Carmem Gottfried, Regina Pessoa-Pureur, Moacir Wajner.   

Abstract

Accumulation of the branched-chain alpha-keto acids (BCKA), alpha-ketoisocaproic acid (KIC), alpha-keto-beta-methylvaleric acid (KMV), and alpha-ketoisovaleric acid (KIV) and their respective branched-chain alpha-amino acids (BCAA) in tissues and biological fluids is the biochemical hallmark of patients affected by the neurometabolic disorder known as maple syrup urine disease (MSUD). Considering that brain energy metabolism is possibly altered in MSUD, the objective of this study was to determine creatine kinase (CK) activity, a key enzyme of energy homeostasis, in C6 glioma cells exposed to BCKA. The cells were incubated with 1, 5, or 10 mM BCKA for 3 h and the CK activity measured afterwards. The results indicated that the BCKA significantly inhibited CK activity at all tested concentrations. Furthermore, the inhibition caused by the BCKA on CK activity was totally prevented by preincubation with the energetic substrate creatine and by coincubation with the N-nitro-L-arginine methyl ester (L-NAME), a nitric oxide synthase inhibitor, indicating that deficit of energy and nitric oxide (NO) are involved in these effects. In contrast, other antioxidants such as glutathione (GSH) and trolox (soluble Vitamin E) were not able to prevent CK inhibition. In addition, we observed that the C6 cells changed their usual rounded morphology when exposed for 3 h to 10 mM BCKA and that creatine and L-NAME prevented these morphological alterations. Considering the importance of CK for brain metabolism homeostasis, it is conceivable that inhibition of this enzyme by increased levels of BCKA may contribute to the neurodegeneration of MSUD patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16633902     DOI: 10.1007/s10571-006-9098-9

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  59 in total

1.  Octamers of mitochondrial creatine kinase isoenzymes differ in stability and membrane binding.

Authors:  U Schlattner; T Wallimann
Journal:  J Biol Chem       Date:  2000-06-09       Impact factor: 5.157

2.  A method for the estimation of serum creatine kinase and its use in comparing creatine kinase and aldolase activity in normal and pathological sera.

Authors:  B P HUGHES
Journal:  Clin Chim Acta       Date:  1962-09       Impact factor: 3.786

3.  Inhibition of brain glutamic acid decarboxylase by phenylalanine, valine, and leucine derivatives: a suggestion concerning the etiology of the neurological defect in phenylketonuria and branched-chain ketonuria.

Authors:  R E TASHIAN
Journal:  Metabolism       Date:  1961-05       Impact factor: 8.694

Review 4.  C-6 glioma cells of early passage have progenitor properties in culture.

Authors:  A Vernadakis; S Kentroti; C Brodie; D Mangoura; N Sakellaridis
Journal:  Adv Exp Med Biol       Date:  1991       Impact factor: 2.622

5.  alpha-Ketoisocaproic acid regulates phosphorylation of intermediate filaments in postnatal rat cortical slices through ionotropic glutamatergic receptors.

Authors:  Cláudia Funchal; Priscila de Lima Pelaez; Samanta Oliveira Loureiro; Lilian Vivian; Franciele Dall Bello Pessutto; Lúcia Maria Vieira de Almeida; Susana Tchernin Wofchuk; Moacir Wajner; Regina Pessoa Pureur
Journal:  Brain Res Dev Brain Res       Date:  2002-12-15

6.  On the mechanisms of neuroprotection by creatine and phosphocreatine.

Authors:  N Brustovetsky; T Brustovetsky; J M Dubinsky
Journal:  J Neurochem       Date:  2001-01       Impact factor: 5.372

Review 7.  The creatine-creatine phosphate energy shuttle.

Authors:  S P Bessman; C L Carpenter
Journal:  Annu Rev Biochem       Date:  1985       Impact factor: 23.643

8.  Responses in primary astrocytes and C6-glioma cells to ammonium chloride and dibutyryl cyclic-AMP.

Authors:  N Haghighat; D W McCandless; P Geraminegad
Journal:  Neurochem Res       Date:  2000-02       Impact factor: 3.996

9.  Differentiated rat glial cell strain in tissue culture.

Authors:  P Benda; J Lightbody; G Sato; L Levine; W Sweet
Journal:  Science       Date:  1968-07-26       Impact factor: 47.728

10.  Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS.

Authors:  Wenhua Zhang; Malini Narayanan; Robert M Friedlander
Journal:  Ann Neurol       Date:  2003-02       Impact factor: 10.422

View more
  4 in total

Review 1.  Cytoskeleton as a potential target in the neuropathology of maple syrup urine disease: insight from animal studies.

Authors:  R Pessoa-Pureur; M Wajner
Journal:  J Inherit Metab Dis       Date:  2007-06-14       Impact factor: 4.982

2.  Inhibition of brain energy metabolism by the branched-chain amino acids accumulating in maple syrup urine disease.

Authors:  César A Ribeiro; Angela M Sgaravatti; Rafael B Rosa; Patrícia F Schuck; Vanessa Grando; Anna L Schmidt; Gustavo C Ferreira; Marcos L S Perry; Carlos S Dutra-Filho; Moacir Wajner
Journal:  Neurochem Res       Date:  2007-08-08       Impact factor: 3.996

Review 3.  Neurological damage in MSUD: the role of oxidative stress.

Authors:  Angela Sitta; Graziela S Ribas; Caroline P Mescka; Alethéa G Barschak; Moacir Wajner; Carmen R Vargas
Journal:  Cell Mol Neurobiol       Date:  2013-11-13       Impact factor: 5.046

4.  Evaluation of plasma biomarkers of inflammation in patients with maple syrup urine disease.

Authors:  Giselli Scaini; Tássia Tonon; Carolina F Moura de Souza; Patricia F Schuck; Gustavo C Ferreira; João Quevedo; João Seda Neto; Tatiana Amorim; Jose S Camelo; Ana Vitoria Barban Margutti; Rafael Hencke Tresbach; Fernanda Sperb-Ludwig; Raquel Boy; Paula F V de Medeiros; Ida Vanessa D Schwartz; Emilio Luiz Streck
Journal:  J Inherit Metab Dis       Date:  2018-05-08       Impact factor: 4.982

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.